SIDIV: towards recognition of the value of in vitro diagnostics

Until then an unsung hero of medicine, in vitro diagnostics is an essential part of the care process: 70% of medical decisions are based on the results it provides. The Syndicate of the In Vitro Diagnostics Industry (SIDIV) is committed on a daily basis to the recognition of the strategic role of in vitro diagnostics in health systems and for patients.

In vitro diagnostics (IVD) holds a special place in the health sector. Used at all stages of the care pathway and throughout the life of patients, it makes it possible to detect and diagnose a patient’s state of health, to prevent and monitor a disease as well as to optimize and guide treatments. It can also be used for health surveillance purposes.

A cutting-edge industry

The activity of the industrialists of the DIV consists in developing, producing and marketing in vitro diagnostic systems: complex tools, intended primarily for healthcare professionals, made up of instruments, reagents, consumables, software and services. A demanding design that uses extremely varied technologies: biology, chemistry, robotics, digital, mechanics, electronics, optics, etc.

The IVD industry represents around a hundred players in France, of all sizes: large international groups, national champions, mid-sized companies, SMEs and start-ups. Spread over the entire territory, it is the source of more than 14,000 direct jobs. With 86% of its turnover generated outside France, the IVD industry actively contributes to France’s international influence.

One of its essential characteristics is its ability to innovate: in France, 11% of the sector’s turnover is devoted to research and development. A capacity for innovation that was brilliantly demonstrated during the Covid-19 pandemic: the IVD is the first health product to have arrived on the market during the COVID crisis. Since then, manufacturers have made new tests available continuously and rapidly according to changes in the health situation and needs; the management of the COVID crisis benefits from a very broad arsenal of tests – molecular, antigenic and serological.

It is a technological sector, innovative, fertile and carrying great medical, scientific and economic value.

At the heart of a value chain

The industrialists of the DIV are the partners of biomedical laboratories and health professionals. They provide them with in vitro diagnostic systems adapted to their needs, ensure the maintenance of the instruments, train the staff in their proper use and in reading the results, which are then provided to the doctor who makes the most appropriate medical decision for the patient. patient.

In vitro diagnostics is an essential element in the medical value chain. Today, more than 70% of medical decisions are made on the basis of in vitro diagnostics. Paradoxically, they only represent 2 to 3% of health expenditure.

Beyond that, IVD is a carrier of efficiency for the healthcare system and of great economic value: it allows savings throughout the patient journey by avoiding unnecessary acts, shortening the length of stays at the hospital. hospital, enabling the right patient to receive the right treatment at the right time for the right duration.

Better access to the innovation market

The resilience of the health system will depend on strengthening the use of in vitro diagnostics in the care pathway and for the benefit of the patient. To do this, the French market must be more attractive and simplified: access to the IVD innovation market must be faster than it is today. Deploying in France derogatory market access mechanisms for innovative diagnostic solutions is essential in order to speed up patient access: there are in fact today tests available in some countries but not in France.

Equally important: IVD innovation must be valued in line with its medical, organizational and economic contribution.

SIDIV: towards recognition of the value of in vitro diagnostics SIDIV

In vitro diagnostics at the heart of the medicine of tomorrow

SIDIV has apparently been heard: the announcements of the ninth CSIS suggest access to simplified diagnostic innovation, thanks to the overhaul of the early access mechanism for diagnostic innovation. This progress should allow IVD to develop and gain even more importance in the coming years. It will be at the heart of tomorrow’s medicine, that of 4P: preventive, prognostic, personalized and participatory.

In view of the value provided and demonstrated during the health crisis, SIDIV pleads for in vitro diagnostics to occupy the place it deserves in the health system for the benefit of patients and for its importance to be rightly recognized and valued to continue. the virtuous circle of long-term innovation, of which we know how essential it has been in the management of the health crisis.


Leave a Reply

Your email address will not be published. Required fields are marked *